Literature DB >> 7704918

Innovations in avoiding particle clearance from blood by Kupffer cells: cause for reflection.

S M Moghimi1, S S Davis.   

Abstract

Therapeutic applications of drug carrier systems following intravenous administration have been limited because of the pronounced tendency of these carriers to localize primarily in Kupffer cells. Recently, attempts have been made to design colloids and drug carrier systems that can be disguised as "self" and remain unrecognizable, at least to a certain extent, by the hepatic macrophages. This review is designed to provide a critical view on fundamentals, current progress, limitations, and future prospects of such engineered colloids and drug carrier systems for intravenous route of administration.

Mesh:

Substances:

Year:  1994        PMID: 7704918

Source DB:  PubMed          Journal:  Crit Rev Ther Drug Carrier Syst        ISSN: 0743-4863            Impact factor:   4.889


  21 in total

Review 1.  Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups.

Authors:  S M Moghimi; A C Hunter
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

2.  Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages.

Authors:  M M Janát-Amsbury; A Ray; C M Peterson; H Ghandehari
Journal:  Eur J Pharm Biopharm       Date:  2010-11-18       Impact factor: 5.571

Review 3.  Strategies in the design of nanoparticles for therapeutic applications.

Authors:  Robby A Petros; Joseph M DeSimone
Journal:  Nat Rev Drug Discov       Date:  2010-07-09       Impact factor: 84.694

Review 4.  Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities.

Authors:  Jessie L-S Au; Bertrand Z Yeung; Michael G Wientjes; Ze Lu; M Guillaume Wientjes
Journal:  Adv Drug Deliv Rev       Date:  2015-12-11       Impact factor: 15.470

5.  In vitro biocompatibility evaluations of hyperbranched polyglycerol hybrid nanostructure as a candidate for nanomedicine applications.

Authors:  Ali Zarrabi; Mohammad Ali Shokrgozar; Manouchehr Vossoughi; Mehdi Farokhi
Journal:  J Mater Sci Mater Med       Date:  2013-11-30       Impact factor: 3.896

6.  Activation of the mononuclear phagocyte system by poloxamine 908: its implications for targeted drug delivery.

Authors:  T I Armstrong; S M Moghimi; S S Davis; L Illum
Journal:  Pharm Res       Date:  1997-11       Impact factor: 4.200

7.  Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery.

Authors:  Jianjun Cheng; Benjamin A Teply; Ines Sherifi; Josephine Sung; Gaurav Luther; Frank X Gu; Etgar Levy-Nissenbaum; Aleksandar F Radovic-Moreno; Robert Langer; Omid C Farokhzad
Journal:  Biomaterials       Date:  2006-10-20       Impact factor: 12.479

Review 8.  Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor.

Authors:  Yinghuan Li; Jie Wang; M Guillaume Wientjes; Jessie L-S Au
Journal:  Adv Drug Deliv Rev       Date:  2011-05-03       Impact factor: 15.470

9.  Development of high drug loaded and customizing novel nanoparticles for modulated and controlled release of Paclitaxel.

Authors:  Primiano Pio Di Mauro; Salvador Borrós
Journal:  Pharm Res       Date:  2014-06-18       Impact factor: 4.200

10.  Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions.

Authors:  Alessandro Parodi; Nicoletta Quattrocchi; Anne L van de Ven; Ciro Chiappini; Michael Evangelopoulos; Jonathan O Martinez; Brandon S Brown; Sm Z Khaled; Iman K Yazdi; Maria Vittoria Enzo; Lucas Isenhart; Mauro Ferrari; Ennio Tasciotti
Journal:  Nat Nanotechnol       Date:  2012-12-16       Impact factor: 39.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.